Tiziana Life Sciences Ltd Current Report (Foreign Issuer)

Tiziana Life Sciences (TLSA) furnished a Form 6-K stating its senior leadership will present a corporate overview at the Jefferies London Healthcare Conference.

Rhea-AI Filing Summary

Tiziana Life Sciences (TLSA) furnished a Form 6-K stating its senior leadership will present a corporate overview at the Jefferies London Healthcare Conference. Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Shah will highlight the company’s innovative pipeline and recent clinical milestones.

The accompanying press release is included as Exhibit 99.1. The information is furnished, not filed, under the Exchange Act and is not incorporated by reference except as specifically stated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 08:30 AM EST Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 13, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that its senior leadership team will present at the prestigious Jefferies London Healthcare Conference. Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Shah will deliver a corporate overview highlighting the Company’s innovative pipeline and recent clinical milestones.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: November 13, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated November 13, 2025

3